- Exchange: New York
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Forest Laboratories Inc
+ Add to WatchlistFRX:US
38.5300 USD 0.1700 0.44%
Share
As of 20:04:04 ET on 05/17/2013.
More on FRX
News for Forest Laboratories Inc (FRX)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Europe Eases Corporate Tax Dodge as Worker Burdens Rise
- E-Books, Sony Music, Glaxo, IBM: Intellectual Property
- Glaxo Sent U.K. Charge Sheet for Paying to Delay Seroxat Copies
- Shire to Forest on Deal List for AstraZeneca: Real M&A
- Percentile of Put vs Call Skew Spread for S&P 500 Companies
- Investors Seek New Highs for Stocks Tied to U.S. Gains
- Forest Wins Denial of Drug Lawsuit Class Certification
- Boehringer Lung Drug Wins U.S. FDA Advisory Panel Backing
- Boehringer’s Lung Drug’s Benefits Questioned
- Richter Falls Most in Seven Weeks on Forest Labs: Budapest Mover
- Forest Labs Falls After Quarterly Loss Exceeds Estimates
- The Top Ten Stocks for Tuesday, January 15
- Depression Tie to Help Lundbeck Pill to Curb Drink Binges
- Lundbeck’s Anti-Alcoholism Pill Wins EU Regulatory Nod
- Richter Rebounds From 6-Month Low on FDA Bid: Budapest Mover
- Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Published May 17, 2013
- Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Published May 16, 2013
- Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013 Published May 14, 2013
- Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Published May 09, 2013
- Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Published May 09, 2013
- Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Published May 02, 2013
- Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Published May 01, 2013
- Ironwood Pharmaceuticals Provides First Quarter 2013 Investor Update Published Apr 23, 2013
- Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Published Apr 23, 2013
- THAILAND GIVES DETAILS OF EXPORTS AND IMPORTS FOR MARCH (THAI) Published Apr 23, 2013
- Adamas Pharmaceuticals Announces Issuance of First US Patent for Nurelin™ (Amantadine HCl Extended Release) Program Published Apr 22, 2013
- Chinese Stocks Rise to Two-Month High, Led by Property Shares Updated 27 minutes ago
- Japan Biotech Ventures Surge as Abenomics Cash Spurs Speculation
- ‘Love Hormone’ Promises Safer Births After Pfizer Flop
- Lundbeck-Takeda Drug Fights Depression Better at Higher Dose
- SAC Says Cooperation With U.S. No Longer ‘Unconditional’
- Credit Swaps in U.S. Fall as Leading Indicators, Sentiment Rise
- Puma Biotech Gains After Rival Drug Data Show No Threat
- J&J Will Stop Sales of Metal-on-Metal Hip Replacements
- Sanofi, French Government at Odds Over Fate of Research Site
- Expected Earnings Growth for Industries in Stoxx 600
- Petrobras, Merck Lead $54 Billion of Company Bond Sales in U.S.
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Lilly, ThyssenKrupp, Adidas, AMD: Intellectual Property
- Glaxo Sees Emerging Market Price Cuts Driving Drug Volume Growth
- Final Soccer World Cup Sponsor to Spend $50 Million in 15 Months
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page